Previous 10 | Next 10 |
BRYAN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that management will participate in Alliance Global Partners’ Virt...
Pfizer and BioNTech's announcement that, based on preliminary data, their COVID-19 vaccine is 90% effective and an emergency use authorization ((EUA)) is only weeks away has led to downward pressure on some of the second tier developers. If all goes according to plan, deployment could start b...
BRYAN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will report its fiscal 2021 first quarter financial results after...
Sorrento currently presents a wide multitude of candidate drugs to combat COVID-19. Due to this huge Covid-19 program, the share price has skyrocketed in recent months, although since the August peak the stock price has been deflating to reach around $7. The problem here is that t...
iBio (IBIO) has appointed Randy J. Maddux as its Chief Operating Officer, effective December 1. Mr. Maddux was most recently SVP and Chief Manufacturing Officer at Aptevo Therapeutics, where he led the company’s quality; process development; analytical development and fo...
BRYAN, Texas, Nov. 03, 2020 (GLOBE NEWSWIRE) -- iBio , Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Randy J. Maddux as its Chief Operating Officer (&...
The Robinhood 100 has become known as a barometer of millennial investing trends due to its focus on the top 100 stocks owned by users of the Robinhood trading platform. But many of the stock on the list are not great companies. Here are five stocks to avoid: Carnival Corporation (CCL), Inovi...
Stocks of coronavirus vaccine developers garnered investors' attention due to their potential to decisively end the COVID-19 pandemic and allow economies to return to normal via mass immunization. Right now, there are nearly 50 experimental SARS-CoV-2 vaccines in clinical trials and 89 va...
The U.S. could authorize emergency use of Moderna's (MRNA) experimental COVID-19 vaccine in December, according to CEO Stéphane Bancel, if the company gets positive interim results in November from a large clinical trial.The comments suggest Moderna's timetable isn't that far off from Pf...
- Adds More Than 25 Years of Financial Leadership in Pharma / Biotech to the Team - - To Chair iBio’s Audit Committee and be Appointed to the Board’s Compensation Committee - BRYAN, Texas, Oct. 15, 2020 (GLOBE NEWSW...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...